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ABSTRACT 
A subpopulation of tumor cells known as ovarian cancer initiating cells (OCICs) have been 
shown to be the cells that propagate the tumor phenotype in ovarian cancer. Studies have showed 
that a very small population (100) of these cells is sufficient to induce a tumor phenotype; while 
a large quantity of tumor cells (5 X 105) are required to induce such a phenotype. In this study 
we studied the functional changes in genes expressed in the OCIC phenotype which were 
important for such efficient propagation of cancers. To enable this analysis, we generated mRNA 
expression and DNA methylation profiles of OCICs and compared them with those of tumor and 
normal ovarian surface epithelial cells. We identified four pathways which regulated most of the 
observed changes and were predicted to be important factors in distinguishing the OCICs from 
tumors and normal cells. The gene signatures for these pathways were analyzed by unsupervised 
clustering in order to determine the similarities of OCICs with respect to tumor and normal 
samples. We further believed that the OCICs can be used as indicators towards the genesis and 
progression of early events in the ovarian cancers. In light of this, we considered two hypotheses 
which are currently addressing the genesis of ovarian cancer. The first hypothesis proposed 
ovarian surface epithelial cells to be cells of origin of the ovarian cancer while the other 
proposed the fallopian tube cells to be contributing the cell of origin for these cancers. It is also 
believed that these two cells can be reciprocal cells of origin for the cancer phenotype. In order 
to test these hypotheses, we integrated the in-house dataset with a public domain fallopian tube 
gene expression data. The integration of the results obtained from these analyses provided better 
understanding of the early events in ovarian carcinogenesis. 
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Chapter 1 INTRODUCTION 
Ovarian Cancer 
 Ovarian cancer is the most lethal gynecological neoplasm, with more than 
100,000 cancer deaths among women worldwide each year, making it as the fifth leading 
cause of cancer deaths among woman (Bowtell, 2010). Moreover, the poor 5-year 
survival (30-40%) results from the high percentage of cases diagnosed at an advanced 
stage and is largely due to the fact that most of them are inoperable when first discovered 
and respond poorly to therapy(Auersperg, Wong, Choi, Kang, & Leung, 2001; Landen, 
Birrer, & Sood, 2008). 
Ovarian cancers according to National Cancer Institute (NCI) are categorized into 
4 stages depending on how far the disease has spread. Stage I means that the cancer has 
been expressed on the ovary only, Stage II the cancer has spread to the pelvis, at Stage III 
the cancer has spread to the abdomen and finally Stage IV is when the cancer has spread 
outside the abdomen. Depending at which stage the disease is diagnosed the survival rate 
will improve dramatically. If the diagnosis is made in the early stages of the disease 
(Stage I) and the patient gets treatment before the cancer spreads outside the ovary, then a 
5 year survival rate of 94% can be achieved. The early physical symptoms of ovarian 
cancer in Stage I and II are common to other benign diseases such as low back pain, 
pelvic discomfort, loss of appetite and others. These are mild symptoms not specific to 
ovarian cancer which makes the early detection harder. The need for a screening test that 
will detect ovarian cancer at the early stages of the disease is clear from these facts. The 
disease prevalence in post-menopause women is 40 in 100000 which leads to strict 
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specificity requirements from a screening test to avoid having too many false positives 
and thus fewer women going through unnecessary operations and treatment. 
Classes of Ovarian Cancer 
Ovarian cancers have been mainly classified into 2 types: Type 1 and Type 2. 
Type 1 tumors include endo-metrioid, mucinous and low grade serous cancers 
which are usually low grade and slowly developing. They show a high frequency of Ras 
pathway mutations and generally lack TP53 mutations. They are shown to have a 
relatively normal karyotype and are often poorly responsive to platinum-based therapy. 
Type 2 tumors are rapidly progressing high-grade serous carcinomas without a 
well defined premalignant lesion. They are strongly associated with TP53 mutations and 
rarely have Ras mutations. This subtype accounts for about 60% to 80% of the cancer 
cases and is the most aggressive. Among these cases, less than 25% are detected at an 
early stage (stages I and II). As Type 2 tumors  account for the bulk of high-grade serous 
ovarian cancer, the terms Type 2 and high-grade are largely equivalent(Bowtell, 2010; 
Levanon, Crum, & Drapkin, 2008). This thesis focuses on the High-grade or Type-2 
serous ovarian cancer (HG-SOC). 
Diagnosis of Ovarian Cancer 
Early diagnosis is of utmost importance for the successful treatment, and survival 
from, ovarian cancer. However, in most of the cases, ovarian cancer is diagnosed at an 
advanced stage when the probability of survival is very less. The prospect of early 
diagnosis is also impeded by several other aspects of the disease. First, in contrast to 
many other malignant diseases the cell of origin of ovarian cancer and the early events of 
ovarian carcinogenesis, have not been clearly identified (Dubeau, 2008). Second, current 
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methods of examination of the ovaries can only be made by invasive diagnostic means, 
that is, via a pelvic examination, including the palpation of the ovaries, and with varying 
success, by ultrasound. In addition, proteins such as CA125 and other tumor markers 
have proved inefficient due to inherent low sensitivity. Methylation markers, however, 
potentially represent a potent new tool for early detection. Aberrant methylation is 
thought to be one of the earliest molecular changes in carcinogenesis (A. P. Bird & 
Wolffe, 1999), and as such can be applied for the detection of early-stage or potentially 
premalignant disease. 
Role of Cancer Stem Cells 
It has been suggested that tumor re-growth, as well as chemotherapy resistance 
and metastasis, are dependent on a small sub-population of cancer cells within the tumor 
that are thought to represent cancer stem cells (CSCs). A defining hallmark of stem cells, 
in both normal and malignant tissue, is the ability to self-renew but simultaneously give 
rise to daughter cells that are committed to differentiation into phenotypes that often 
cross lineages. To achieve this, stem cells can undergo an asymmetric cell division 
whereby they segregate cell fate determinants into only one of the two daughter cells 
(Knoblich, 2008). In adult mammals, stem cells have been characterized for a number of 
tissues, including the blood system, central nervous system, muscle, colon, breast, and 
bone/cartilage. 
For cancer stem cells in solid tumors, much can be learned from studies of 
hematopoietic stem cells (HSC) for which it has been shown that the transplantation of a 
single cell into a myeloablated recipient can reconstitute the entire blood system. This 
definitive HSC gives rise to a hierarchy of pluripotent progenitors that become 
4 
 
progressively restricted in their differentiation potential. Leukemia is thought to originate 
either from HSCs that acquired genetic or epigenetic changes and became partially 
differentiated and tumorigenic, or from progenitors that acquired the capacity to self-
renew (Passegue, Jamieson, Ailles, & Weissman, 2003). The existence of stem cells for 
certain types of leukemia is strongly supported by lentiviral tagging of human acute 
myelogenous leukemia cells and the observation of individual clones present in NOD–
SCID mice after serial transplantation of the tagged cells (Hope, Jin, & Dick, 2004). 
Studies of leukemia stem cells also indicated great phenotypic plasticity depending on the 
stage of tumor growth, tumor microenvironment, and external factors such as stress 
created by radio-or chemotherapy (Passegue, et al., 2003).The presence of CSCs in solid 
tumors has been proposed for human cancers including breast (Al-Hajj, Wicha, Benito-
Hernandez, Morrison, & Clarke, 2003), brain (Galli et al., 2004), colon (O'Brien, Pollett, 
Gallinger, & Dick, 2007), head and neck (Prince et al., 2007), pancreatic (Ophorst et al., 
2007), prostate (Collins, Berry, Hyde, Stower, & Maitland, 2005), ovarian (Baba et al., 
2009; Bapat, Mali, Koppikar, & Kurrey, 2005; Zhang et al., 2008), and skin cancer (Fang 
et al., 2005). The characteristics of solid tumor stem cells have been defined as ‘‘a small 
subset of cancer cells within a cancer that constitute a reservoir of self-sustaining cells 
with the exclusive ability to self-renew and to cause the heterogeneous lineages of cancer 
cells that comprise the tumor’’ (Clarke et al., 2006). Several cell surface markers, 
including CD24, CD44, CD133, CD166, EpCAM, or dye efflux assays have been used to 
sort populations of putative cancer stem cells from primary tumor cultures or cell 
suspensions obtained from tumor biopsies. After transplantation into immunodeficient 
mice, tumors form from several hundred marker-positive cells, whereas for marker 
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negative cells orders of magnitudes higher numbers are needed to achieve the same 
frequency of tumor formation (Gupta, Chaffer, & Weinberg, 2009). Recently, using an 
improved xenotransplantation technique, a study with human melanoma cells showed 
tumor formation after inoculation of one tumor cell (Quintana et al., 2008) and thereby an 
important step towards the proof of CSC existence was made (Strauss et al., 2011). 
Epigenetics 
The epigenome provides a mechanism of cellular memory and is key in regulating 
and deciphering stages of normal and abnormal cellular development, including phases of 
growth, differentiation, senescence, aging and immortalization during carcinogenesis 
(Feinberg & Tycko, 2004). The components of the epigenome, DNA methylation, post-
translational histone and other protein modifications, nucleosome positioning and 
noncoding RNAs (specifically microRNA [miR] expression), act in concert to exert their 
cellular effects (Sharma, Kelly, & Jones, 2010). 
Epigenetics is defined as the study of heritable changes in gene regulation without 
a change in the DNA sequence or the sequence of proteins associated with DNA. Histone 
modifications and DNA methylations are the most studied epigenetic changes in cancer 
biology. DNA methylation primarily occurs in the CpG dinucleotides and is often altered 
in the cancer cells. Both hypomethylation and hypermethylation contribute to 
tumorigenesis. Gene-specific hypermethylation is observed in many different types of 
cancers and is often seen responsible for the silencing of tumor suppressor genes (Jones 
& Laird, 1999). On the other hand, hypomethylation is responsible for the development 
of genomic instability mostly by the activation of oncogenes or loss of imprinting which 
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is frequently observed in cancer (Feinberg & Tycko, 2004; Liu, Wylie, Andrews, & 
Tollefsbol, 2003). 
Histone modifications are also important in cancer biology and are responsible for 
major changes in chromatin structure affecting the accessibility of DNA to the 
transcription factors which regulate gene expression. Mainly, histone acetylation has been 
known to increase the gene expression affecting from the uncoiling of the chromatin thus 
making the DNA accessible to the transcription factors. On the other hand histone 
deacetylation leads to coiling of the chromatin structure thus preventing gene expression 
as the DNA is rendered inaccessible to the transcription factors(Verdone, Caserta, & Di 
Mauro, 2005). Other types of histone modifications like histone methylation show varied 
effects and all these alterations together seen in cancer have major role in the initiation of 
cancer and its progression to potentially malignant cells (Lehrmann, Pritchard, & Harel-
Bellan, 2002). However, for this study we focus mainly on DNA methylation and its role 
in cancer which will be discussed in detail further. 
DNA Methylation 
DNA methylation is an addition of a methyl group to the C-5 position of a 
cytosine residue, usually in the context of CpG dinucleotides (A. Bird, 2002; Das & 
Singal, 2004).  As the only known mammalian modification of DNA itself (Robertson, 
2005), DNA methylation is essential for parental imprinting, embryonic development, 
gene regulation, and chromosomal stability (Bartolomei & Tilghman, 1997; Herman, 
1999; Jaenisch, Beard, Lee, Marahrens, & Panning, 1998; Li, Bestor, & Jaenisch, 1992).  
The link between DNA methylation and cancer dates back to 1983, when various 
investigators found that cancer cells possess an inverse methylation pattern to that of 
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normal cells (Feinberg & Tycko, 2004).  In normal cells, the genome is overall 
hypermethylated, especially in repetitive genomic elements (A. Bird, 2002), while small 
stretches of CG-rich promoter regions, “CpG islands” (CGI), remain largely 
unmethylated (Baylin, 2005).  In tumor cells, however, global DNA hypomethylation is 
observed while CGI, by contrast, acquire hypermethylation (Jones & Baylin, 2002).  This 
aberrant CGI hypermethylation typically leads to silencing of associated coding 
sequences, providing an alternative to mutation or deletion for the inactivation of tumor 
suppressor genes (Luczak & Jagodzinski, 2006; Nephew & Huang, 2003).  DNA 
methylation is catalyzed by a group of DNA methyltransferases (DNMTs): DNMT1, 
DNMT2, DNMT3A and DNMT3B (Pradhan & Esteve, 2003).  DNMT1 primarily 
maintains pre-existing genomic methylation patterns, methylating hemimethylated DNA 
during DNA replication (Bestor, Laudano, Mattaliano, & Ingram, 1988).  DNMT3A and 
DNMT3B, by contrast, are mainly responsible for de novo methylation, methylating both 
unmethylated and hemimethylated DNA with equal efficiency (Okano, Takebayashi, 
Okumura, & Li, 1999; Xie et al., 1999).  The function of DNMT2 is little known, but has 
recently been reported to be a methyltransferase that uses tRNA as a substrate (Goll et al., 
2006). 
Despite the role of promoter CGI methylation in tumorigenesis, recent studies 
indicate that it may also play a prominent role in the complexity of cancer drug resistance 
(Fojo & Bates, 2003).  One extensively studied example is the DNA mismatch repair 
enzyme human Mut-L homologue (hMLH1).  As a key component in the mismatch repair 
system, hMLH1 recognizes drug-DNA adducts and initiates drug-induced apoptosis 
(Vaisman et al., 1998).  Epigenetic silencing of hMLH1 by methylation leads to 
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diminished apoptosis response to bulky drug-DNA adducts, and therefore is one 
contributing factor to drug-resistance development (Balch et al., 2005; Siddik, 2003).  
Besides hMLH1, several other chemotherapy responsive genes are also deregulated 
during the acquisition of chemoresistance (Fraser et al., 2003; Grossman & Altieri, 2001; 
Pommier, Sordet, Antony, Hayward, & Kohn, 2004). 
Recently, the technological advancements have enabled quantitative assessments 
of thousands of loci for DNA methylation status, thus providing an opportunity to study 
the epigenetic signature of a cell. This rich source of information can be used to better 
understand the steps of carcinogenesis and their cells of origin. Further it can be used to 
identify appropriate model systems for further studies and also to identify potential 
biomarkers detection, classification and monitoring or the disease (Houshdaran et al., 
2010).  
Techniques in DNA methylation studies 
DNA methylation has been historically studied in a locus-targeted manner. 
However, with the advent of highthroughput platforms, large-scale structure of genomic 
methylation patterns is available through genome-wide scans. Two high-throughput 
platforms that have been popularly used include the Illumina Infinium Human 
Methylation27 array and the Illumina GoldenGate array. Both arrays are based on 
genotyping bisulfite (BS)-converted DNA. DNA samples are treated with a methylation 
kit that converts unmethylated cytosines to uracils, whereas methylated cytosines are 
protected and remain cytosine. Therefore, whether the base at a given locus is converted 
or not provides information on its original methylation status. The results of the array, the 
methylation status of the interrogated CpG site is a sequence of β-values, one for each 
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locus, calculated as the average of approximately 30 replicates (with approximately 30 
beads per site per sample) of the quantity max(M, 0)/(max(U,0)1max(M,0)1100). Here U 
is the fluorescent signal from an unmethylated allele on a single bead, M is that from a 
methylated allele. A maximum between signal intensity and 0 is chosen to compensate 
for negative signals due to background subtraction. The constant 100 is to regularize b-
values when both M and U values are small (Bibikova et al., 2006). 
As explained earlier, β-value ranges continuously from 0 (unmethylated) to 1 
(completely methylated) and reflects the methylation level of each CpG site. It can be 
thought of as a ratio of the methylated (or unmethylated) probe intensity and the overall 
intensity (sum of methylated and unmethylated probe intensities). According to the 
notation used by Illumina methylation assay, Beta-value for an ith interrogated CpG site is 
defined as: 
 
where yi,menty and yi,unmenty are the intensities measured by the ith methylated and 
unmethylated probes, respectively. To avoid negative values after background 
adjustment, any negative values will be reset to 0. Illumina recommends adding a 
constant (stated earlier) offset α (by default, α = 100) to the denominator to regularize 
Beta value when both methylated and unmethylated probe intensities are low. The Beta-
value statistic results in a number between 0 and 1, or 0 and 100%. Under ideal 
conditions, a value of zero indicates that all copies of the CpG site in the sample were 
completely unmethylated (no methylated molecules were measured) and a value of one 
indicates that every copy of the site was methylated (Du et al., 2010). 
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Recently, tremendous amounts of DNA methylation data have been generated 
from high- throughput DNA methylation platforms. Currently, to select differentially 
methylated loci, researchers mainly apply either parametric methods such as regression-
based methods or t-test or nonparametric methods such as rank sum test. Many studies 
have shown that β-values generated by BeadStudio with Illumina arrays usually have a 
heavy tail close to zero which represents unmethylated and a bump close to one which 
represents completely methylated. One such study by Shuang Wang (Wang, 2011) 
studied these patterns and proposed statistical approaches for analyzing the methylation 
data. This study used a β-value threshold of 0.5 to differentiate between unmethylated 
and completely methylated loci, with those above β-value of 0.5 considered as 
completely methylated and the loci below as unmehtylated. They further proposed a 
method to select differentially methylated loci between ovarian cancer cases and age-
matched healthy controls using Illumina Infinium Human Methylation27 Beadchip 
(Teschendorff et al., 2010) and identified some methylation loci that are missed by the 
existing method.  
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Chapter 2 BACKGROUND 
Predictions for the Cell of origin in Ovarian Cancer 
It has been thought that serous ovarian cancer (SOC) arise from ovarian surface 
epithelium or intra-ovarian inclusion cysts. This theory has recently been challenged by 
the identification of tubal intraepithelial carcinoma (TIC) in woman with BRCA1 or 
BRCA2 mutations found in the distal end of fallopian tube which is proposed as probable 
precursors of advanced HG-SOC. The gene signatures of fallopian tube epithelium and 
HG-SOC are found to be similar and the coexistence of TIC with similar TP53 mutations 
support the theory that fallopian tube is an important site for the initiation of high-grade 
serous ovarian cancer (HG-SOC). However, the contribution of fallopian sites to the 
genesis of HG-SOC is unclear at present. The wide-spread growth of tumor tissue in 
advanced cancers usually obscures the primary site of origin. Even though the primary 
tumor seems to originate from the ovary, the theory suggests that the fallopian tube may 
have provided the originating cell supposedly through entrapment in the ovary 
(endosalpingiosis)(Bowtell, 2010). 
Ovarian Cancer Initiating Cells 
  In a previous study, Zhang et. al isolated and characterized ovarian cancer 
initiating cells (OCICs) using primary human ovarian tumors. These OCICs were seen to 
be fully capable of reestablishing their original tumor phenotype in vivo. These cells 
could be isolated using antibodies against CD44 and CD117. These could propagate 
tumors in animals and fulfilled the current cancer stem cell criteria including self-
renewal, small minority of total tumor population, reproducible tumor phenotype, 
multipotent differentiation into nontumorigenic cells and having distinct cell surface 
antigenic phenotype, permitting consistent isolation.  
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This study further investigated the tumorigenic potential of CD44+CD117+ cells (Cells 
having these markers) compared to that of CD44-CD117- (Cells without the markers). 
They observed that as few as 100 cells with the markers were required to result tumor 
formation in mice, whereas 5 X 105 cells without the markers were required to develop 
the tumor. 
These cells have been thought to provide a better insight into the genesis of the 
ovarian cancer. The speculated origin for the OCICs is the ovarian surface epithelium 
(OSE). This is based on the fact that like OCICs, OSE are also known to express CD44 
and CD117 surface markers. However, based on the histology and gene expression 
patterns, the ovarian cancers are hypothesized to be derived from fallopian Tube 
epithelial cells. This is because the ovarian tumors are known to become epithelial during 
tumor progression. On the other hand, OSE are known to retain capacity to undergo 
epithelial-to-mesenchymal transition required for postovulatory repair mechanism. It is 
thought that the comprehensive studies of epigenetic patterns (Histone modifications & 
DNA Methylation) in OCICs will lead to better understanding of the early events in 
ovarian cancer(Zhang, et al., 2008). 
Epithelial – Mesenchymal Transition 
The changes observed in the cell phenotypes between epithelial and mesenchymal 
states are defined as epithelial – mesenchymal (EMT) and mesenchymal – epithelial 
(MET) transitions. They have been known to play a key role in the process of embryonic 
development and also have recently known to be important for the pathogenesis of 
various cancers. EMT is a complex program through which an epithelial cell loses its 
characteristic differentiated phenotype by the accompanied loss of functions like cell-cell 
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adhesion, lack of motility, planar and apical-basal polarity. It in-turn acquires 
mesenchymal characteristics like motility, invasiveness and increased resistance to 
apoptosis.  
 
Figure 1: Epithelial-to-Mesenchymal Transition and the Mesenchymal-to-Epithelial 
Transition in Ovarian Cancer (Polyak & Weinberg, 2009) 
EMT has been known to be the important factor in the metastatic dissemination, 
invasiveness and resistance to therapy. On the other hand MET is the reversal of EMT 
and is observed after the dissemination and is responsible for the formation of metastases 
in remote locations. However, unlike embryogenesis, these programs in cancer are mostly 
irreversible events as they are caused due to somatic mutations (Polyak & Weinberg, 
2009). 
TGF-β Signature 
The Transforming growth factor-β (TGF- β) family of cytokines has been known 
to induce the process of EMT during the embryonic development, various diseases and 
cancer pathogenesis. However, recently TG1F- β has been shown to play a critical role in 
the regulation of breast cancer stem cell phenotypes. It has known to induce EMTs 
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through multiple signaling mechanisms which include phosphorylation by the receptors 
of SMAD transcription factors and proteins present in the cytoplasm, regulating cell 
polarity and formation of tight junctions. In the mammary epithelial cells, it is known that 
TGF- β type II receptor directly phosphorylates SMAD2, SMAD3 and protein regulation 
cell polarity PAR6A. The phosphorylation of this protein (PAR6A) reduces the apical-
basal polarity and consequently the tight junctions between adjacent epithelial cells are 
dissolved. TGF- β is also known to affect the activities of various other EMT-inducing 
pathways like Notch, Wnt and integrin signaling which act together to induce EMT 
programs (Polyak & Weinberg, 2009). 
DNA Methylation Studies in Ovarian Cancer 
There have been various molecular approaches to identify tumor markers for the 
diagnosis and prognosis of ovarian cancer including complementary DNA microarrays. 
DNA methylation studies have been mostly investigating the methylation patterns based 
on supervised and unsupervised cluster analysis for identifications of different 
phenotypes and genes specific to them. Houshdaran et. al studied the methylation profiles 
of ovarian epithelial tumors and ovarian cell lines. They used Illumina GoldenGate 
platform with 1505 CpG sites representing 808 genes for studying 15 ovarian cell lines 
and 27 primary tumors. They considered measurements with a detection p-value less than 
0.05 to have signal intensity significantly above background. They masked the data 
points with a detection p-value greater than 0.05 as “NA” considered them to be 
representing the beta values with non-significant detection of DNA methylation 
compared to background. Further, to identify the loci with significantly different levels of 
DNA methylation in cell lines compared to tumors, they restricted the analysis to 1,110 
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CpG sites whose beta-values were variable across samples. For this they considered those 
CpG sites which had minimum beta-value greater than 0.2, ratio of maximum beta-value 
to minimum beta-value greater than or equal to 2 and, 1 or fewer missing beta-values. 
They further performed two-sampled t-test for the 15 cell lines with 27 tumors and 
adjusting the p-values from the t-test for multiple comparisons by controlling the FDR. In 
the process, they identified 489 CpG sites representing 337 genes that varied significantly 
in the DNA-methylation at FDR less than 1%. They further identified that most of these 
i.e. 445 of 489 were highly methylated in cell lines compared to tumors. From this study 
they indicated the difference in DNA methylation profiles between ovarian cancers cell 
lines and tumors this emphasizing the cautiousness required in using the cell lines as 
models for tumors in further molecular studies. They also identified the different 
methylation patterns in the histological subtypes of ovarian cancer viz. Serous, 
Endometroid and Clear Cell carcinomas(Houshdaran, et al., 2010). 
Another study by Michaelson-Cohen et. al used a genome-wide approach for 
identifying de novo methylated genes in epithelial ovarian cancer. They used methyl-
DNA Immunoprecipitation and CpG Island microarrays for studying methylation patterns 
for 4 epithelial ovarian serous carcinoma and 2 normal ovarian tissue samples. After 
comparing these tissue types they identified 2583 islands that were constitutively 
methylated in most tissue types and 2484 (96%) of them were also methylated in the 
normal ovary. They further identified 16,962 unmethylated CpG Islands in normal ovary 
and found that 376 (2.16%) of these were methylated in ovarian cancer thus stating them 
as de novo methylated. Also, out of the 6,498 CpG islands that were methylated in 
normal ovary, 582 (9%) underwent demethylation in ovarian cancer. This implies that 
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these 582 islands were previously methylated in normal and underwent demethylation in 
cancer. However this study emphasized an unclear biological significance of the later 
group in tumorigenesis. It was also observed that the large number of normally 
methylated islands on the inactivated X chromosome underwent demethylation in ovarian 
cancer. This study thus provided a new perspective on methylation in ovarian cancer in a 
genome-wide approach. It also illustrated the way genes were silenced by methylation of 
CpG island and that the silenced genes played significant roles in the cell differentiation 
and functioning thus indicating potential biomarkers for diagnosis, prognosis and 
treatment of cancer(Michaelson-Cohen et al., 2011). 
The Cancer Genome Atlas (TCGA) is a comprehensive and coordinated effort to 
accelerate our understanding of the molecular basis of cancer through the application of 
genome analysis technologies, including large-scale genome sequencing. TCGA is a joint 
effort of the National Cancer Institute (NCI) and the National Human Genome Research 
Institute (NHGRI), two of the 27 Institutes and Centers of the National Institutes of 
Health, U.S. Department of Health and Human Services. TCGA undertakes 
comprehensive genomic characterization and analysis of each cancer and makes the data 
freely available to the cancer community through its data portal. It examine up to 500 
samples for each tumor type thus providing statistical power to generate comprehensive 
genomic profiles of each cancer required for identification the best targets for drug 
development. For the entire sample types, both the normal and cancerous tissues are 
collected which allows identification of genomic changes that play roles in development 
of that particular cancer. Ovarian serous cystadenocarcinoma is the cancer being studied 
by TCGA and is a type of epithelial ovarian cancer which accounts for about 90 percent 
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of all ovarian cancers. The study mainly aims to determine gene expression patterns 
which are linked to differences in patient survival, to establish whether certain gene 
changes are linked to response to therapy and define the role of copy number variation 
(abnormal duplications or deletions) in cancer development. One of the findings of this 
study report is the identification of 4 subtypes of high grade serous ovarian cancer using 
583 tumor samples. These subtypes include immunoreactive, differentiated, proliferative 
and mesenchymal. These were obtained by performing an integrated analysis of mRNA, 
miRNA expression and DNA methylation data from TCGA("Integrated genomic 
analyses of ovarian carcinoma," 2011).  
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Significance of studying OCICs 
Ovarian cancer initiating cells have yet to be studied for specific changes in the 
expression patterns of genes and their corresponding methylation patterns. The study of 
changes in the pathways regulated by these genes will give us an insight in the 
progression and proliferation of ovarian cancer. Also these cells can be used as models 
for the studies on the genesis of ovarian cancer and also for testing the various 
hypotheses concerning the cell of origin. The inclusion of these cells for the comparison 
studies of tumors with fallopian epithelial cells and ovarian surface epithelial cells can 
help in determining the earlier events in the development of ovarian cancer. 
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Chapter 3 Hypotheses 
Based on this information we formulated two hypotheses which will be tested by the 
studies in this thesis 
1. Comparison of ovarian cancer initiating cells (“OCIC”) gene expression and DNA 
methylation profile to normal ovarian surface epithelium (“nOSE”) and bulk 
population tumor cells (“tumor”) can provide insight into specific 
pathways/processes involved in the initiation and progression of ovarian cancer 
(HG-SOC). 
2. Comparison of gene expression signature concordances of ovarian cancer-
initiating cells (OCICs) and various fallopian cancers/tissue and ovarian 
cancer/tissue can provide insight into the cell(s)-of-origin of high-grade serous 
ovarian cancer (HG-SOC). 
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Chapter 4 METHODS 
Approach  
In order to evaluate the proposed hypothesis, we formulated specific workflows 
for each separately. As these analyses required preprocessing of the raw datasets, they 
had to undergo various rigorous quality control steps which will be explained in the 
future sections. For the comparison of ovarian cancer initiating cells with tumors and 
normal cells, we developed a systematic workflow shown in Figure 1. Here we analyzed 
differentially expressed and methylated genes for similarly altered gene ontology 
pathways and also verified them by performing gene set enrichment analysis (GSEA) in 
case of expression datasets. 
 
Figure 2: Analysis of Ovarian Cancer Initiating Cells using the gene expression and 
DNA methylation Datasets. 
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After determining the similarly altered pathways between these datasets, we set 
out to identify relevant gene signatures which will be efficient in indicating the difference 
in the three phenotypes. Using the information on these pathways and combining them 
with information from the literature, we identified these gene signatures. Further, we 
performed unsupervised cluster analysis for the two datasets separately for the genes in 
the signatures to get an indication of the differences in the signature patterns among the 
three phenotypes. 
For the comparisons of ovarian cancer initiating cells with the fallopian tube 
datasets, we employed a separate workflow. This was mainly due to the fact that the 
fallopian tube data was obtained from a public domain source (Tone et al., 2008) which 
was obtained using a different platform and had to be integrated with the in-house 
ovarian cancer initiating cell data. This process included steps for the integration and 
removal of the platform bias induced due to the use of different platforms between the 
two datasets. This process has been explained in detail in the later sections. The overall 
approach for testing the second hypothesis can be seen in the Figure-2. 
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Figure 3: Comparison of Ovarian cancer initiating cells with Fallopian Tube cells. 
After the integration of the two datasets, the comparison was performed using the 
gene signatures identified in the first hypothesis to identify the similarities and 
differences between the tumors compared to the fallopian epithelial cells and the ovarian 
surface epithelial cells and also to observe the classification of OCICs with respect to 
these phenotypes. 
Data Collection 
The identification and collection of high quality datasets was of utmost 
importance for correct evaluation of the proposed hypotheses. The samples used in this 
study were taken mainly from three sources. One of these sets belonged to the samples 
prepared at Indiana University from the Nephew lab consisting of Ovarian cancer 
initiating cells and ovarian surface epithelium, here indicated as in-house dataset; the 
other belonged to a study by Tone et. al which studied the Fallopian Tube epithelium and 
Fallopian Tumors. The third data set was obtained from the data made available by The 
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Cancer Genome Atlas consortium for ovarian tumors. The details of these data sets will 
be explained here. 
In-house Dataset 
The tumor samples were obtained from patients with stage III serous 
adenocarcinomas. These samples were minced, suspended in DMEM/F12 medium 
(Invitrogen), and mixed with 300 units/mL of both collagenase (Invitrogen) and 
hyaluronidase (Calbiochem), which was followed by overnight incubation (37oC, 5% 
CO2). These enzymatically disaggregated suspensions were then filtered (40-µm cell 
stainer) and washed twice with PBS, and RBCs were removed by Histopaque-1077 
(Sigma). As a result, single tumor cells were obtained which were placed under stem cell 
conditions by re-suspension in serum-free DMEM/F12 supplemented with 5 µg/mL 
insulin (Sigma), 20 ng/mL human recombinant epidermal growth factor (EGF; 
Invitrogen), 10 ng/mL basic fibroblast growth factor (bFGF; Invitrogen), and 0.4% 
bovine serum albumin (BSA; Sigma), which was followed by culturing in Ultra Low 
Attachment plates (Corning) and subsequent organization into spheres (Zhang, et al., 
2008). 
The ovarian cancers initiating cells were obtained by fluorescence-activated cell 
sorting tumors. This was carried out by disassociating small pieces of tumors into single 
cells followed by washing and removing RBCs. Cells were then suspended in 2% 
BSA/PBS and labeled with anti-CD44, anti-CD117, and secondary antibodies which 
were phycoerythrin-labeled and FITC-labeled respectively. The isolation of CD44+, 
CD117+, or CD44+CD117+ cells was performed using FACSAria flow cytometer and 
analysed by WinMDI. The cells were sorted twice to assess the OCIC enrichment and 
purity. Further, the normal ovarian surface epithelial cells were obtained from consented 
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individuals who showed no signs of ovarian cancer.  These methods were all performed 
at Indiana University in the Nephew lab and are also explained in a previous study by 
Zhang et.al (Zhang, et al., 2008). 
The samples belonging to the three phenotypes explained above i.e. Tumor, 
Ovarian Cancer Initiating Cells and normal Ovarian Surface Epithelium were further 
used for generating high-throughput Gene Expression and Methylation data. RNA was 
obtained from these samples using the standard Qiagen RNeasy purification kits. The 
RNA extracted from three samples each for Tumor and OCIC (tumor and OCIC from 
each patient i.e. 3 patients) where as five samples for normal OSE were selected for 
generating the gene expression data using the Affymetrix gene-1.0-st arrays. The 
standard procedures for the quality and quantity assessments from Affymetrix were 
followed. The intensity data obtained from these arrays was further processed for dye-
bias and normalization techniques explained in further sections. Further tumor and OCIC 
samples from the same three patients used for gene expression studies were used for 
obtaining DNA methylation profiles. Methylation data was also obtained for two normal 
Ovarian Surface Epithelium samples. The genomic DNA was obtained using standard 
Qiagen DNeasy purification kits and was subject to sodium bisulfide conversion, labeled 
with fluorescent dyes and then hybridized to Illumina HumalMethylation 27K bead 
arrays. The methods and reagents for the sodium bisulfide conversion and array 
hybridization were performed based on the standard Illumina protocols. The methylation 
intensity data obtained was further processed for dye bias and normalization techniques 
explained in further sections. 
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Public Domain Data 
Fallopian Tube Datasets 
The data was obtained from a study conducted by Tone et. al (Tone, et al., 2008). 
The study collected samples for normal fallopian tube epithelial cells (FTEn) from 
individuals who did not show adnexal malignancy or family history and also did not test 
positive for BRCA1/2 mutations. They further collected samples for thirteen serous 
carcinoma samples (SerCa) out of these, six samples showed tubal (FTSerCa) and seven 
showed ovarian (OVSerCa) origin. RNA from the study cases was obtained using 
NuGEN Biotin Ovation kit (NuGEN Technologies). Further the RNA was subject to 
cDNA synthesis which was amplified and purified, enzymatically fragmented and labeled 
with biotin. The quality and quantity was assessed based on the Affymetrix standard 
protocols and then the purified labeled cDNA product was hybridized to Affymetrix 
GeneChip U133A Plus 2.0 arrays. The raw data intensities were deposited in National 
Center for Biotechnology Information Gene Expression Omnibus resource under the 
accession number GSE10971. This data was obtained from GEO for the further analysis 
in this thesis. The obtained raw data was integrated with the in-house data followed by 
multiple normalization steps explained in later sections. 
The Cancer Genome Atlas Dataset 
The samples in TCGA are collected from newly diagnosed patients with ovarian 
serous adenocarcinoma who were undergoing surgical resection and had received no 
prior treatment for their disease including chemotherapy or radiotherapy. DNA and RNA 
were isolated from the tissue using an AllPrep DNA/RNA mini kit (Qiagen). The datasets 
used in this thesis are the raw data from TCGA representing a total of 584 samples that 
were used for obtaining gene expression genome wide expression data whereas 534 
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samples were used for obtaining DNA methylation profiles. The gene expression profiles 
were obtained by using Affymetrix HT Human Genome U133 Arrays. The DNA 
methylation profiles were obtained by using Illumina HumanMethylation 27k Arrays 
similar to the platform used for the in-house dataset. These datasets were further subject 
to integration with the in-house datasets followed by multiple normalization procedures 
in order to assess the quality of the in-house dataset. This will be explained in the later 
sections. 
Quality Analyses 
Gene Expression 
As explained earlier, the in-house dataset used the Affymetrix gene-1.0-ST arrays 
for obtaining the gene expression profiles for the tumor, OCIC and normal OSE 
phenotypes. A number of normalization approaches were considered for the 
normalization of the raw data. MAS5 algorithm from Affymetrix adjusts the perfect 
match (PM) probes by effectively subtracting the signal found on the mismatch (MM) 
probes. This subtraction is done carefully to avoid producing negative signals and to 
minimize the effect of outliers. However in the case of Affymetrix gene-1.0-st arrays, it 
does not report the information for mismatch (MM) probes, instead all the probes in this 
array are considered perfect match (PM) which gives it the ability of genome wide 
coverage. Thus, Robust Multichip Average (RMA) approach is suitable as it does not 
involve an implicit subtraction of the MM probe values. Instead, RMA looks at the 
distribution of the PM probe values and fits a combination of two distributions, a "noise" 
distribution that is normally distributed, and a "signal" distribution that is distributed like 
an exponential distribution. The normalized values are estimated through the expected 
value of the signal distribution. The raw data was thus normalized using the default RMA 
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algorithm which involves RMA background correction, Quantile normalization and 
summarization of the intensities by the Median Polish method were performed. The 
summarized signals were then log base 2 transformed for each probe set. 
The normalized datasets for in-house samples were further evaluated using 
principal component analysis (PCA) using Partek. The PCA indicated that the samples 
representing the same phenotype were well correlated with each other and at the same 
time, the three phenotypes were well divergent from each other. This can be seen in 
Figure-3. 
 
Figure 4: Principal Component analysis of gene expression profiles for the in-house 
dataset. 
 
The integration of the fallopian tube dataset that used the Affymetrix Human 
Genome U133 Plus 2.0 Arrays however involved many subsequent steps. After the RMA 
normalization and the steps described above, the integration step involved the mapping of 
probes between the two platforms. This was achieved using the sequence matching 
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information retrieved from Affymetrix depicting the similarity of probes between the two 
platforms. Only that probe match information was used which was classified as good 
match by Affymertix (The sequence matching between the two probes showed percent 
identity greater than 90%). The integration retained 85.89% of the total genes present in 
both the platforms. The distribution of data after the integration of the two platforms was 
plotted and can be seen in the Figure-4. 
 
Figure 5: Plot showing the distribution of the data after the integration of the 
Fallopian Tube data (1 to 37) and in-house (38 to 48). 
A clear indication of the presence of a platform bias could be seen from the 
integrated data. In order to normalize for this platform bias we employed series of 
statistical and biological validation filters. In order to normalize the datasets statistically 
we first employed Median normalization in order to center the intensities from the two 
arrays on a common median. Further assuming that the two arrays have common 
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distribution of intensities, we employed quantile normalization. The distribution achieved 
after each of these normalizations can be seen in Figure-5 and Figure-6 respectively. 
 
Figure 6: Plot showing the distribution of the integrated data after median 
normalization showing Fallopian Tube data (1 to 37) and in-house (38 to 48). 
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Figure 7: Plot showing the distribution of the integrated data after Quantile 
normalization showing Fallopian Tube data (1 to 37) and in-house (38 to 48). 
The data obtained after quantile normalization seemed to be evenly distributed 
across the samples for both the arrays. However, to confirm the removal of platform bias 
from the further analysis, we increased the stringency by applying a biological filter. In 
order to do this, we determined the ovarian serous carcinoma (OVSerCa) samples from 
fallopian tube dataset and the Tumors form in-house dataset belonged to the same 
phenotype i.e. high-grade serous ovarian carcinoma (HG-SOC). Based on this fact, 
biologically, there should be no differentially expressed probes between these two 
samples and the ones which are differentially expressed can be considered as a platform 
bias and should not be included in further analysis. Taking this into consideration, we 
performed a differential expression analysis on the quantile normalized data for the 
OVSerCa and in-house Tumor phenotypes. This was done using a two sided Student’s T-
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test. The probes having a p-value less than 0.05 were considered significantly 
differentially expressed and were removed from the further analysis. The remaining 
probes represented 50% of the total genes originally covered by the two platforms. 
However, a Gene Ontology analysis on the 50% genes removed from further analysis 
indicated most of the enriched biological process were involved in development of 
differentiation processes which can be thought of mostly the properties of housekeeping 
genes. The remaining 50% of the genes in that were included in the dataset can be said to 
be the important indicators of the differences in the phenotypes in the progression of 
cancer. 
In order to test the consistency of this approach, we used similar normalization 
steps described above to integrate the in-house tumors with 584 TCGA tumor samples 
which also match the biological phenotype being ovarian serous adenocarcinoma. After 
the integration and subsequent normalization procedures, we performed unsupervised 
hierarchical clustering (using Multi-Experiment Viewer) separately for the in-house data 
integrated with fallopian tube dataset and for the in-house data integrated with the 584 
TCGA tumors. The clustering patterns obtained for the two comparisons can be seen in 
the Figure-7 and Figure-8 respectively. 
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Figure 8: Unsupervised cluster analysis for the in-house data and fallopian tube 
dataset. 
 
Figure 9: Unsupervised cluster analysis for the in-house data and 584 TCGA 
Tumors. 
From the above clustering patterns observed for the two separate analyses, we can 
see that as the tumors consistently cluster together with the tumors from the public 
domain datasets, OCICs are seen to cluster consistently with normal OSE cells. This 
indicated that even though this stringent normalization approach removes significant 
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amount of genes from further analysis, the remaining genes will be significant and 
efficient as indicators for differentiation between phenotypes. 
DNA Methylation 
The studies of the methylation profiles were performed using the Illumina 
HumanMethylation 27k platform. This platform provides the intensities in the methylated 
and unmethylated channels based on the methylation content in the CpG islands. This 
data was further normalized using the standard normalization algorithms proposed by 
Illumina using the normalization functions in the Methylumi Package in R programming 
language (Du, Kibbe, & Lin, 2008). The normalization itself is carried out in a number of 
steps. The data is first normalized for dye bias, followed by median normalization by 
inspecting the median intensities in methylated and unmethylated channels at very low 
and very high beta values. Finally, a new beta value is calculated as a ratio of methylation 
intensity and the sum of the intensities in the methylated and unmethylated channels. This 
beta value ranges from 0 to 1, where the values closer to 0 indicate unmethylated CpG 
islands while the values closer to 1 indicate methylation in the CpG islands. The 
biological interpretation can be thought of as the value of 0 will indicate both the alleles 
are unmethylated, a value of 0.5 will indicate that one of the alleles is methylated and 
value closer to 1 indicates both the alleles are methylated. The distribution of the beta 
values for the Tumor samples can be seen in the Figure-9. 
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Figure 10: Distribution of Beta values for the Tumor samples. 
The normalized datasets for in-house samples were further evaluated using 
principal component analysis (PCA) using Partek. The PCA indicated that the samples 
representing the same phenotype were well correlated with each other and at the same 
time, the three phenotypes were well divergent from each other. This can be seen in 
Figure-10. 
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Figure 11: Principal Component Analysis of the Methylation data representing 
three phenotypes.  
In the case of TCGA methylation datasets, studies were carried out using the same 
platform used here and similar normalization approach was used for these datasets. The 
TCGA included methylation profiles for 534 ovarian serous carcinoma tumors which 
were integrated by matching with the probes from the in-house dataset. In order to test 
whether the profiles for in-house tumors represented the ovarian serous carcinoma 
phenotype, an unsupervised cluster analysis was performed for this integrated data. This 
can be seen in the Figure-11. 
36 
 
 
Figure 12: Unsupervised hierarchical clustering of in-house dataset with TCGA 
dataset. 
It was seen that the ovarian tumor methylation profiles for in-house tumors 
clustered with TCGA tumors indicating that the in-house tumors clearly represent the 
ovarian serous carcinoma phenotype. Moreover, it was observed that the OCIC and 
normal OSE showed completely distinct methylation profile compared to the tumors. 
Statistical Analyses 
Various statistical approaches were used for both the methylation and gene 
expression data in further analyses. These included differential comparisons between the 
samples, Gene ontology analysis, Gene set enrichment analysis, unsupervised 
hierarchical clustering analysis. The details on each of these techniques will be explained 
here. 
Differential Analysis 
Differential analysis was carried out for both the DNA methylation and gene 
expression datasets. However, the stringency criteria differed for each of these datasets 
based on the nature of the data. The normalized gene expression data was used for the 
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comparisons of differential expression using two sided Student’s T-test over each 
comparison i.e. OCIC Vs nOSE, OCIC Vs Tumor and Tumor Vs nOSE. For each of the 
comparison fold change values were calculated separately from the raw data. Genes were 
then filtered using a T-test p-value where probes with p-value less than 0.01 were 
selected, then followed by twofold change cutoff, where the previously filtered genes 
were scanned for the genes which had a fold change difference of greater than 2. A 
similar analysis was carried out for the methylation data with the inclusion of another 
filter which checked the methylation status for the pair in the comparison. For this filter, 
a beta cutoff of 0.5 was used (determined based on the information from the literature and 
the distribution of beta intensities in the samples), where all the beta values above 0.5 
were considered hypermethylated and those below 0.5 were considered unmethylated. 
For the differential methylation analysis it was confirmed that if one of the pairs of 
intensities in the comparison is hypermethylated then the other should be unmethylated 
and vice versa. 
Gene Ontology (GO) and Gene set enrichment analysis (GSEA) 
The gene ontology analysis was mostly carried out on the datasets that were 
selected for further functional analysis in the various approaches. On the other hand gene 
set enrichment analysis was carried out in order to test the enrichment of the gene sets 
and individual genes in that particular gene set that were selected for further studies. The 
GO analysis was mainly carried out using default GO settings used in DAVID functional 
annotation tool (Huang da, Sherman, & Lempicki, 2009). The gene set enrichment 
analysis was carried out using GSEA tool from the Broad institute (Subramanian et al., 
2005). 
38 
 
Unsupervised Hierarchical Clustering 
The unsupervised hierarchical clustering has been extensively used in this thesis. 
All the clustering results were obtained by using MultiExperiment Viewer (MeV) a tool 
that is part of the TM4 Microarray Software Suite (Saeed et al., 2006). In hierarchical 
clustering, genes with similar expression patterns are grouped together and are connected 
by a series of branches, which is called clustering tree (or dendrogram). Experiments with 
similar expression profiles are also grouped together using the same method. Here we 
used Pearson correlation coefficient to measure the similarity between gene and sample 
profiles.  A Pearson correlation coefficient indicates the relationship between two ordered 
sets of gene expression data for several different conditions.  It indicates both how the 
two sets are related and the strength of that relationship.  For example, if gene A 
increases over time and gene B decreases proportionally, their correlation value will be -
1.0 because they are perfectly divergent.  If the two sets were not perfectly divergent, but 
still diverged, the correlation would remain negative, but would be greater than -1.0.  In 
contrast, if genes A and B increase proportionally over time, then their correlation will be 
1.0.  If genes A and B have absolutely no relationship to each other whatsoever, their 
correlation will be 0. Once we have a table of correlation values between all the genes, 
clustering is performed with the genes having high correlation values grouped together. 
By retracing the order in which the genes were progressively joined into clusters and by 
knowing the correlation value of each step, we can map out which genes are related to 
each other closely and which genes are related only distantly.  This is represented 
graphically as the tree and the scale represents the Pearson correlation coefficient for the 
genes.  
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Chapter 5 RESULTS 
Gene Expression 
Based on the differential expression analysis of gene expression data explained 
earlier, the filtered genes were classified into groups which were specific to each of the 
particular phenotypes. A clustering showing these groups can be seen in the Figure-12. 
 
Figure 13: Gene Expression Clustering of the filtered genes. 
The genes specific to each of the phenotypes were further studied for the 
enrichment of specific biological pathways by performing GO analysis. The genes 
identified in the specific pathways determined from the GO analysis were further used as 
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gene sets for determining their enrichment on the gene expression data using the gene set 
enrichment analysis approach on the OCIC compared to rest of the phenotypes. 
 
Figure 14: Gene Ontologies for genes specifically up-regulated in each of the 
phenotype. 
The gene ontologies enriched in each of the phenotype were obtained based on 
the gene specifically up-regulated in each of the tumor, OCIC or normal OSE 
phenotypes. The ontology terms indicated in red indicate the processes that were found to 
be unique to that phenotype. These were considered relevant for further analysis 
approaches. The main terms representing the OCIC specific phenotype were related to 
Cell cycle and DNA repair processes. For the Tumor specific genes, the enrichment was 
observed mostly for the terms related to immune-response, whereas in case of normal 
OSE, most of the processes belonged to the basic signaling pathways. The genes 
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belonging to the pathways that were considered relevant from the gene ontology analysis 
were further tested for the enrichment of the gene sets using GSEA. 
 
Figure 15: GSEA for the gene sets related to GO enriched processes carried out on 
entire dataset for the comparison of OCIC with Rest of the phenotypes. 
The GSEA revealed the pathways and gene sets identified unique for OCIC were 
indeed enriched significantly in the OCICs compared to the tumor and normal OSE 
phenotypes. It was seen that the gene sets related to Cell Cycle, Cell differentiation and 
Hypoxia pathways were significantly enriched in OCICs. 
DNA Methylation 
In order to identify the pathways altered specifically in each phenotype especially 
due to the alteration in the methylation patterns in the three phenotypes, genes that were 
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hypermethylated specifically in these phenotypes were selected. We considered genes 
with beta intensities greater than 0.5 to be hypermethylated, thus filtering out the genes 
that showed unmethylation i.e. beta intensity less than the above define threshold. 
 
Figure 16: Genes hypermethylated in each phenotype. The genes indicated in 
shaded regions can be considered specific to that phenotype and were used for 
further analysis. 
The above filtering provided a list of genes for each phenotype indicated in 
Figure-15. It was observed that a total of 5581 genes were hypermethylated in OCICs out 
of which 1021 genes belonged specifically to OCICs. In case of Tumors, 5,736 genes 
were found to be hypermethylated out of which 819 genes were specifically methylated 
in tumors. Whereas, out of 4,645 genes that were hypermethylated in normal OSE, only 
281 were seen to be specifically hypermethylated in this phenotype. These specifically 
hypermethylated genes in each phenotype were subjected to further gene ontology 
analysis to identify altered pathways. 
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Figure 17: Gene Ontology analysis for specifically hypermethylated genes in each 
phenotype. 
From the gene ontology analysis it was found that the most of the cell 
development related pathways were hypermethylated in OCICs which can correspond to 
silencing of their genes and functions. In the case of tumor specific genes, it was seen that 
most of the immune response and mesenchymal to epithelial transition related pathways 
were hypermethylated. Also in the case of genes specifically hypermethylated in normal 
OSE, most of the processes related to cell cycle and DNA repair pathways were seen to 
be hypermethylated and hence can be thought of as silenced. 
Determination of Signature Pathways 
Based on the biological processes that were enriched in the expression and 
methylation analyses explained above, we determined the processes that contributed to 
various signature pathways that were known to be related to or contributing in the 
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development of tumor phenotypes in various cancers. The genes belonging to these 
signature pathways were instrumental in differentiating between the different tumor 
phenotypes and the cell types known to promote cancer phenotypes. We determined four 
important signatures from literature that were known to be related to ovarian cancers that 
are known to show enrichment of the identified gene ontologies and involved in cancer 
progression. 
• Epithelial to mesenchymal transition. 
• TGF-beta signaling pathway. 
• WNT signaling pathway. 
• Notch signaling pathway. 
The details about these pathways and their results for the expression and methylation 
datasets are explained further. 
Epithelial – Mesenchymal Transition Signature 
As explained earlier, EMT is the process by which an epithelial cell becomes 
more mesenchymal (Valcourt, Kowanetz, Niimi, Heldin, & Moustakas, 2005). The 
signature was obtained from a recent study conducted by Taube et al. on human breast 
cancer cells (Human mammary epithelial cells or HMLE) (Taube et al., 2010). The EMT 
core signature was obtained by inducing HMLE cells to express genes like GSC, Snail, 
Twist and TGF-β1 or the knock down of the expression of gene E-cadherin (These genes 
have been known to be responsible to induce an EMT process in cells eventually 
converting the epithelial cells to mesenchymal phenotype.). The resulting set of gene 
expression changes between the two phenotypes was defined as the EMT core signature. 
This signature included 159 down-regulated and 87 up-regulated genes (showing atleast 
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2-fold change) which was obtained from all of the EMT inducing signals discussed 
above. The study also indicated that the use of the total mRNA isolated from entire 
tumors may preclude the detection of cells that have undergone EMT as only a small 
proportion of the neoplastic cells in each tumor may exhibit the EMT phenotype. It is 
also indicated that FOXC1 gene expression correlated with a poor survival among the 
breast cancer patients. 
Unsupervised Cluster analysis  
An unsupervised cluster analysis was performed for each of the signature datasets 
of EMT i.e. the clustering was performed on up-regulated and down-regulated genes 
separately. The clustering was performed for both gene expression and DNA methylation 
data. It showed a clear distinction between the normal OSE and tumor phenotypes. The 
normal OSE showed a clear adherence to the mesenchymal phenotype such that most of 
the genes that were included in the up-regulated signature were also up-regulated in 
normal OSE and vice versa (for down-regulated signature). On the other hand, tumor 
showed a clear epithelial phenotype as most of the up-regulated signature genes were 
down-regulated in tumor and vice versa (for down-regulated signatures). In case of 
OCIC, they clustered with normal OSE for both the signature gene sets suggesting an 
inclination toward mesenchymal phenotype. The clustering patterns for both the 
signatures can be seen in Figures 18 and 19. In the case of methylation intensities, the 
clustering patterns for both the signature gene sets showed similarities in the tumor and 
normal patterns but OCICs seemed to have a great difference in the methylation patterns 
as more genes were methylated in OCICs compared to tumors and normal cells. 
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Figure 18: Unsupervised Clustering of Expression and Methylation intensities for 
genes Up-regulated in EMT signature. 
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Figure 19: Unsupervised Clustering of Expression and Methylation intensities for 
genes Down-regulated in EMT signature. 
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TGF-β Signature 
As explained TGF- β is known to be a precursor pathway for the induction of 
EMT. The TGF- β signature studied here was obtained from a recent study by Valcourt et 
al. (Valcourt, et al., 2005). This study was carried out on mouse mammary epithelial cells 
which were stimulated for a considerable amount of time with TGF- β1, to induce the 
EMT programs, consequently inducing a mesenchymal phenotype. The treated cells and 
the normal epithelial cells were compared for the gene expression patterns and the genes 
differentially expressed between the two phenotypes were selected. It was seen that 344 
independent genes were regulated by TGF- β1 out of which, 205 (60%) were shown to be 
up-regulated and 139 (40%) were down-regulated in the EMT induced cells compared to 
normal epithelial cells. These gene sets were used for the further analysis. 
Unsupervised Cluster Analysis 
An unsupervised cluster analysis involving the gene expression and methylation 
data was carried out for both the up-regulated and down-regulated gene signatures. The 
clustering showed that the tumors and OCICs showed similar clustering patterns 
however, the correlation of the similarities were low in both the clustering of up-
regulated and down-regulated genes. In both the cases, the normal OSE cells showed 
agreement with the mesenchymal phenotype as the genes up-regulated in the signature 
were also up-regulated in normal OSE and those that were down-regulated were also 
down-regulated in normal. The methylation profiles for the clustering analysis in both the 
signature gene sets showed methylation patterns fairly similar for tumor and normal OSE, 
whereas the patterns observed for OCICs greatly diverged from the tumor and normal 
with the number of methylated genes being more in OCICs. 
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Figure 20: Unsupervised Clustering of Expression and Methylation intensities for 
genes Up-regulated in TGF-beta signature 
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Figure 21: Unsupervised Clustering of Expression and Methylation intensities for 
genes Down-regulated in TGF-beta signature 
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The expression patterns of TGF- β were further studied by looking at the genes 
differentially expressed in the tumor and OCIC phenotypes compared to normal OSE. 
The genes were selected based on the differential expression criteria (explained in 
methods section) and also the fold change. This analysis was performed on the genes 
represented in the TGF-beta signaling pathway annotated in the KEGG database. The 
details of this analysis can be seen in Figures 22 and 23. It was seen in case of tumors that 
most of the genes in the upstream of the signaling pathway were down-regulated whereas 
most of the genes contributing in Apoptosis and Cell Cycle were showed to be up-
regulated. A similar expression pattern was seen for OCICs where some of the genes in 
the upstream of the signaling pathway were up-regulated. The major difference between 
the tumors and OCICs was that TGF- β was up-regulated in OCIC where as it was down-
regulated in tumors. 
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Figure 22: Differential analysis for TGF-beta signaling pathway for OCIC 
compared to normal OSE. 
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Figure 23: Differential analysis for TGF-beta signaling pathway for Tumor 
compared to normal OSE. 
As TGF-beta regulated wide range of functions like proliferation, apoptosis, 
differentiation and especially migration, the results obtained in this analysis suggests that 
the TGF-beta signaling pathway seems to be active in OCIC where as it is inactive in 
tumor cells. This indicates the OCICs being more predisposed to the properties like 
migration compared to tumor. 
Methylation Signature 
Another signature gene set which showed enrichment for biological processes related to 
TGF-β and EMT signaling was obtained by Matsumura et al. The signature included the 
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genes proposed in the study to be commonly methylated in cancer. This signature 
indicated the biological and clinical relevance of DNA methylation in ovarian cancer 
(Matsumura et al., 2011). 
Signature 
This signature was obtained form a study of ovarian cancer data. The signature 
contained 378 genes that were identified by growing cultures in the presence or absence 
of DNMT inhibitors. It was found that the signature included many TGF-beta related 
genes and the study suggested that the age related epigenetic modifications lead to 
suppression of TGF-beta pathway. This was stated based on the hierarchical clustering 
that was performed on the 378 genes and the corresponding generation of clusters that 
were strongly correlated with TGF-beta pathway activity shown to be discriminate 
patients based on age. The cells in the cultures were treated with DNA-hypermethylating 
agents like 5-aza-2’-deoxycytidine (decitabine or 5-Aza-dc) or 5-azacytidine (5-Azac), 
followed by gene expression microarray analysis in order to detect genes likely to have 
been silenced by DNA methylation in cancer. The gene ontologies enriched in this set 
included adhesion, cell-migration, angiogenesis and immune-response which are all 
relevant to the functions of TGF-beta super family pathway. 
Unsupervised Hierarchical Clustering  
An unsupervised hierarchical clustering analysis was performed on the 378 genes 
found to be commonly methylated in ovarian cancer. From the analysis shown in Figure-
24 it was seen that majority of the signature genes were methylated and silenced in OCIC 
compared to Tumor and normal OSE. Consistent with the clustering patterns observed in 
previous analysis, methylation patterns for tumors were similar to normal, whereas 
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OCICs showed a great divergence form the two phenotypes with more number of genes 
seen to be methylated. 
 
Figure 24: Unsupervised Clustering of genes commonly methylated in cancer. 
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Wnt signaling pathway 
The Wnt proteins are secreted morphogens that are mainly required for basic 
developmental processes, such as cell-fate specification, progenitor-cell proliferation and 
the control of asymmetric cell division, in many different species and organs. According 
to the KEGG annotation, there are at least three different Wnt pathways: the canonical 
pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the 
canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the 
stabilization of cytoplasmic beta-catenin through inhibition of the beta-catenin 
degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-
regulated genes through its interaction with TCF (T-cell factor) family transcription 
factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling 
leads to the activation of the small GTPases RHOA (RAS homologue gene-family 
member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and 
ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to 
remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ 
signalling is mediated through G proteins and phospholipases and leads to transient 
increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein 
kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase 
calcineurin. 
Unsupervised Cluster Analysis 
The signature gene set for Wnt signaling pathway was retrieved from MSigDB 
which is a database hosted by Broad Institute (Subramanian, et al., 2005). The gene set 
included a total of 89 genes which were shown to be integral genes in the Wnt signaling 
pathway. A hierarchical clustering of both the DNA methylation and gene expression 
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intensities revealed that most of the genes were similarly expressed in tumors and OCICs. 
The OCIC samples clustered with tumor samples with a very significant correlation of 
greater than 0.7 signifies the close similarities in the expression patterns in the two 
phenotypes. The methylation patterns observed in this signature is consistent with 
previous analysis suggesting more methylation observed in genes belonging to OCIC 
compared to tumor and normal OSE cells, whereas the later phenotypes show less 
differences in the methylation patterns. OCIC on the other hand showed great divergence 
in the methylation patterns compared to the other two phenotypes. 
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Figure 25: Unsupervised clustering of the genes from WNT signaling pathway from 
KEGG. 
The expression patterns of Wnt signaling pathway were further studied using 
differential expression in the genes belonging to tumor and OCIC phenotypes compared 
to normal OSE. The genes were selected based on the differential expression criteria 
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(explained in methods section) and also the fold change. The details of this analysis can 
be seen in Figures 26 and 27. Consistent with the unsupervised analysis, the differential 
expression patterns showed similar gene expression patterns in the Tumor and OCIC cells 
with some differences in the expression of few downstream genes. Some of these genes 
which regulate cell cycle process were upregulated in OCIC but down-regulated in 
Tumors. 
 
Figure 26: Differential analysis for Wnt signaling pathway for OCIC compared to 
normal OSE. 
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Figure 27: Differential analysis for Wnt signaling pathway for Tumor compared to 
normal OSE. 
Based on the differential analysis it could be said that the Wnt signaling pathway 
being responsible for many of the basic developmental processes is downregulated in 
both the tumor and OCIC phenotypes. This suggests that the OCIC share the expression 
patterns found in the tumor cells with an addition of the upregulation of genes responsible 
for cell cycle and cell proliferation.   
Notch Signaling Pathway 
The Notch signaling pathway is an evolutionarily conserved, intercellular 
signaling mechanism essential for proper embryonic development in all metazoan 
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organisms in the animal kingdom. According to the KEGG annotation, the Notch proteins 
(Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta 
(or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are 
transported to the plasma membrane as cleaved, but otherwise intact polypeptides. 
Interaction with ligand leads to two additional proteolytic cleavages that liberate the 
Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates 
to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a 
histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an 
activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited 
to the NICD-CSL complex, leading to the transcriptional activation of Notch target 
genes. 
Unsupervised Cluster Analysis 
The signature gene set for Notch signaling pathway was retrieved from MSigDB 
(Subramanian, et al., 2005). The gene set included a total of 47 genes which were shown 
to be integral genes in the Notch signaling pathway. A hierarchical clustering of both the 
DNA methylation and gene expression intensities revealed that most of the genes were 
similarly expressed in tumors and OCICs. The OCIC samples clustered with tumor 
samples with a very significant correlation of greater than 0.8 which signifies the close 
similarities in the expression patterns in the two phenotypes. The methylation patterns 
observed in this signature is consistent with previous analysis suggesting more 
methylation observed in genes belonging to OCIC compared to tumor and normal OSE, 
whereas the later phenotypes show less differences in the methylation patterns. OCIC on 
the other hand showed great divergence in the methylation patterns compared to the other 
two phenotypes. 
62 
 
 
Figure 28: Unsupervised clustering of the genes from Notch signaling pathway from 
KEGG. 
The expression patterns of Notch signaling pathway were further studied using 
differential expression in the genes belonging to tumor and OCIC phenotypes compared 
to normal OSE. The genes were selected based on the differential expression criteria 
(explained in methods section) and also the fold change. The details of this analysis can 
be seen in Figures 29 and 30. Consistent with the unsupervised analysis, the differential 
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expression patterns showed similar gene expression patterns in the Tumor and OCIC cells 
with some differences in the expression of few up-stream genes.  
 
Figure 29: Differential analysis for Notch signaling pathway for OCIC compared to 
normal OSE. 
 
Figure 30: Differential analysis for Notch signaling pathway for Tumor compared to 
normal OSE. 
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It was seen that the Notch gene which regulates normal gene regulation through 
MAPK signaling pathway was seen to be significantly down-regulated in OCIC which 
was not evident in tumor as the change in the gene expression for tumor was not 
significant for Notch gene. On the other hand, the Fringe genes which are important for 
the working of the Notch signaling was seen to be upregulated in OCIC but down-
regulated in Tumors. As the OCICs cluster closely with tumors, and as the notch 
signaling is known to be responsible for intercellular communication which is usually 
disrupted in cancer, the analysis suggests the similar disruption in the cellular 
communication can be prevalent in OCICs. 
Comparison with Fallopian Tube Datasets 
As explained earlier, the public domain fallopian tube dataset included three main 
phenotypes, Fallopian Tube Epithelial Normal Cells (FTEn), Fallopian Tube Serous 
Carcinoma (FTSerCa) and Ovarian Cancer Serous Carcinoma (OVSerCa). The tumors 
from the in-house dataset were matched and integrated with the OVSerCa phenotype as 
stated earlier. The integrated datasets were further used for unsupervised hierarchical 
clustering and differential expression analysis which will be discussed here. The 
integrated dataset was tested with the similar gene signatures determined in the earlier 
analysis with intent to compare the expression patterns of OCICs as precursor of Tumors 
with Fallopian Tube cells and in the process speculate on the genesis of ovarian cancer 
based on the similarities in expression patterns of OCIC with either normal OSE or 
Fallopian tube epithelium. 
Epithelial – Mesenchymal Transition Signature 
The signature for EMT which was used earlier with two datasets; up-regulated 
and down-regulated was again used for this analysis. Out of a total of 91 up-regulated 
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signature genes, the integrated dataset contained information for 63 genes, whereas out of 
the 159 down-regulated genes, the data was available for 82 genes. 
 
Figure 31: Unsupervised clustering of the up-regulated genes from the EMT 
signature. 
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Figure 32: Unsupervised clustering of the down-regulated genes from the EMT 
signature. 
As observed in the earlier analysis of EMT signature, it was seen that OCICs 
show a mesenchymal phenotype where as Tumors show an epithelial phenotype. This can 
be seen from the above clustering patterns, the OCICs cluster closely with nOSE cells 
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where most of the down regulated genes in the signature are seen to be down regulated in 
these two phenotypes and the upregulated genes in the signature seen to be upregulated. 
This is consistent with the fact that biologically normal OSE cells are known to be 
mesenchymal showing the EMT process to be active. On the other hand, the Tumors 
cluster closely with the normal Fallopian tube epithelial cells which show all the 
epithelial properties where EMT processes are inactive. The tumors thus can be said to 
show an epithelial phenotype. Further, the normal OSE and Fallopian tube cells are 
highly divergent form each other clustering significantly away from each other, showing 
distinct gene expression patterns.  
TGF-beta Signaling Pathway Signature 
As stated earlier, TGF-beta signaling regulated wide range of cellular functions 
such as cell proliferation, apoptosis, cell differentiation and migration. In order to study 
the similarities between tumors and Fallopian tube epithelial cells, we studied the TGF-
beta signature from MSigDB which provides all the genes in the TGF-beta pathway 
annotated in KEGG database. The signature included 86 genes which were known to play 
an important part in the TGF-beta signaling pathway. Out of these genes, intensity 
information was available for 47 genes in the integrated dataset. 
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Figure 33: Unsupervised clustering of the genes from the TGF-beta signature. 
Consistent with the TGF-beta signature studied earlier, we observed that the 
OCICs cluster together with tumors and in this case also with normal fallopian tube 
epithelial samples. This suggests that the TGF-beta signaling patterns observed in tumors 
and OCICs were more similar to those in fallopian epithelial cells than the ovarian 
surface epithelial cells. The expression patterns of normal OSE were again vastly 
different to normal Fallopian tube epithelial calls. The signature was further studied by 
performing differential analysis between the Tumors and OCICs compared to the 
fallopian tube epithelial cells. The details of this analysis for the TGF-beta signaling 
pathway are illustrated in the Figures 35 and 35. 
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Figure 34: Differential analysis for TGF-beta signaling pathway for OCIC 
compared to normal Fallopian Tube epithelial cells. 
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Figure 35: Differential analysis for TGF-beta signaling pathway for Tumor 
compared to normal Fallopian Tube epithelial cells. 
It was observed that most of the genes regulating the TGF-beta signaling pathway 
were upregulated in both the Tumor and OCICs compared to fallopian tube epithelium. 
This analysis confirmed that the genes involved in the TGF-beta pathway showed similar 
expression patterns for both the OCICs and Tumors compared to the fallopian tube 
epithelial cells showing an upregulation of the TGF-beta signaling pathway. 
Wnt signaling pathway 
The signature genes representing the Wnt pathway that were explained in the 
earlier analysis were again used in this analysis for the comparison of OCICs with the 
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fallopian tube epithelial cells. As stated earlier, Wnt pathway regulates many basic 
developmental processes like cell-fate specification, progenitor cell proliferation and the 
control of asymmetric cell division, the inactivation of this pathway is a signature of the 
tumor phenotypes which lead to asymmetric regulation of the above pathways leading to 
cancer. The comparison of this signature with the Fallopian tube samples will indicate 
their similarities to the epithelial phenotype. The clustering of OCIC and Tumors 
compared to the fallopian tube and ovarian surface epithelial cells can be seen in Figure-
36. It was seen that the expression data was available for only 75 genes in the integrated 
data out of the total 151 genes in the signature. 
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Figure 36: Unsupervised clustering of the genes from the WNT Signature. 
The clustering patterns of OCICs were shown to be more similar to the tumors 
where, both tumors and OCICs clustered with epithelial cells compared to the normal 
OSE cells. This signature thus indicates the similarities in the Tumors and epithelial cells 
with the OCICs. This was further tested using differential expression analysis on this 
signature. The differentially expressed genes between the tumor and OCIC compared to 
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Fallopian epithelial cells can be seen in Figures 37 and 38. The comparison will indicate 
the similarities and differences of the expression patterns in OCICs and Tumors. 
 
Figure 37: Differential analysis for Wnt signaling pathway for OCICs compared to 
normal Fallopian Tube epithelial cells. 
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Figure 38: Differential analysis for Wnt signaling pathway for Tumor compared to 
normal Fallopian Tube epithelial cells. 
The differential expression analysis revealed that the expression patterns for 
OCICs and Tumors are very similar compared to Fallopian Tube epithelial cells. It was 
seen that Wnt genes were mostly down-regulated in OCICs and Tumors which is similar 
to the results for the comparison with the normal OSE cells. It was also seen that 
consistent with the previous analysis, some of the cell cycle regulating genes were down 
regulated in tumor but were up-regulated in OCICs. Overall, the expression patterns 
found in the differential comparisons of the comparisons with the Fallopian tube and 
normal OSE showed similar expression patterns for both phenotypes. 
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Notch Signaling Pathway 
The signature genes representing the Notch signaling pathway that were explained 
in the earlier analysis were again used in this analysis for the comparison with the 
fallopian tube epithelial cells. As stated, Notch pathway regulates many important 
processes like inter-cell communication, cell differentiation and cell fate decisions; the 
inactivation of this pathway is a signature of the tumor phenotypes which lead to 
asymmetric regulation of the above pathways leading to cancer. The comparison of this 
signature with the Fallopian tube samples will indicate their similarities to the epithelial 
phenotype. The clustering of OCIC and Tumors compared to the fallopian tube and 
ovarian surface epithelial cells can be seen in Figure-39. It was seen that the expression 
data was available for only 24 genes in the integrated data out of the total 47 genes in the 
signature. 
 
Figure 39: Unsupervised clustering of the genes from the Notch Signature. 
Even though the numbers of genes were less in this signature, the clustering 
patterns of OCICs were shown to be more similar to the tumors where, both tumors and 
OCICs clustered with epithelial cells compared to the normal OSE cells with a greater 
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than 0.8 correlation. This signature thus indicates the similarities in the Tumors and 
epithelial cells with the OCICs. This was further tested using differential expression 
analysis on this signature. The differentially expressed genes between the tumor and 
OCIC compared to Fallopian epithelial cells can be seen in Figures 40 and 41. The 
comparison will also indicate the similarities and differences of the expression patterns in 
OCICs and Tumors. 
 
Figure 40: Differential analysis for Notch signaling pathway for OCICs compared to 
normal Fallopian Tube epithelial cells. 
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Figure 41: Differential analysis for Notch signaling pathway for Tumor compared to 
normal Fallopian Tube epithelial cells. 
The differential expression analysis revealed that the expression patterns for 
OCICs and Tumors are very similar compared to Fallopian Tube epithelial cells. It was 
seen that Notch genes were mostly up-regulated in OCICs and Tumors which is contrary 
to the results for the comparison with the normal OSE cells where Notch was down-
regulated. These expression patterns found in the differential comparisons with the 
Fallopian tube and normal OSE suggest that the Notch pathway is active in tumors and 
OCICs with respect to the epithelial cells but its activation is not at the levels of the 
mesenchymal cells, thus suggesting them to be intermediates between the mesenchymal 
and epithelial phenotypes. 
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Chapter 6 DISCUSSION 
Role of ovarian cancer initiating cells in cancer development and 
progression 
Recently a subpopulation of tumor cells known as ovarian cancer initiating cells 
(OCICs) have been shown to be the cells that propagate the tumor phenotype in ovarian 
cancer. The studies have showed that a very small population (100 cells) of these cells are 
sufficient to induce a tumor phenotype, while a large quantity of cells (5 X 105) cell are 
required to induce such a phenotype in xenotransplanted mouse. In this thesis we studied 
the functional changes in genes present in the OCIC phenotype which were important for 
such efficient propagation of cancers. To enable such analysis, we generated mRNA 
expression and DNA methylation profiles of OCICs and compared them with those of 
Tumor and normal ovarian surface epithelial cells. From these analyses and also from 
various studies in literature which analyzed similar cells in other cancers, we determined 
four pathways which regulated most of the observed changes and were predicted to be 
important factors in distinguishing the OCICs from Tumors and normal cells. We 
identified gene signatures from the literature which were regulated by these pathways and 
performed unsupervised cluster analysis on these signatures in order to determine the 
similarities of OCICs with respect to tumor and normal samples. 
These analyses gave us a better understanding of the OCICs. We determined that 
even though OCICs have been isolated from the Tumor cells, they show distinct gene 
expression and DNA methylation profiles. These cells were found to be an intermediate 
subtype between the mesenchymal and epithelial phenotypes. They were shown to retain 
some of the EMT signature gene profiles form normal ovarian surface epithelial cells 
which showed OCICs to be mesenchymal by clustering them with the mesenchymal 
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normal OSE cells. On the other hand, for the cancer related pathways like TGF-beta, Wnt 
and Notch, the OCIC cells shared expression profiles with tumor cells, thus making them 
altered cells similar to tumors. The OCICs consistently showed methylation profiles 
distinct from the tumors and normal OSE cells for all the signatures. They also showed 
significantly more genes to be hypermethylated than the other two phenotypes for all the 
signatures thus indicating a scope of using the genes from these signatures as DNA 
methylation markers. 
The down-regulation of the tumor suppressor pathways in OCICs could explain 
their ability to propagate tumors. On the other hand, the mesenchymal properties allow 
them to migrate and form metastases. These properties are symbolic of a cancer 
phenotype. On the contrary, even though the tumor cells showed down regulation of 
tumor suppressor pathways which can enable them to propagate the tumors, they showed 
an epithelial phenotype. This epithelial phenotype of the tumors eliminates the possibility 
of these cells to migrate and in turn forming metastases. The analysis suggests that the 
OCICs are the small populations of tumors that retain the mesenchymal or migratory 
characteristics while the other tumor cells lack this property. 
Insight in the genesis of ovarian cancer 
We believed that the OCICs can be used as indicators towards the genesis and 
progression of early events in the ovarian cancers. In light of this, we considered two 
hypotheses which are currently addressing the genesis of ovarian cancer. The first 
hypothesis proposed ovarian surface epithelial cells to be cells of origin of the ovarian 
cancer while the other proposed the Fallopian Tube cells to be contributing the cell of 
origin for these cancers. It is also believed that these two cells can be reciprocal cells of 
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origin for the cancer phenotype (Landen, et al., 2008). In order to test these hypotheses, 
we integrated the in-house dataset with a public domain Fallopian tube gene expression 
data. 
The comparison of the OCICs with the fallopian tube cells revealed that as the 
tumors become more epithelial during their proliferation, most of the tumor related 
pathways show expression patterns which are similar to the epithelial cells for tumors and 
also for OCICs. The exception to this pattern is the EMT signature which indicated that 
the OCICs are closer to the normal OSE cells showing a mesenchymal phenotype for 
both. The interesting fact consistent for all the comparisons was that the normal OSE 
were shown to be highly divergent form fallopian epithelial cells for all the signatures. 
The analysis thus gives an indication of normal OSE cells to be the cells of origin 
as OCIC being the precursors of tumors, can be thought to retain the mesenchymal 
properties from OSE cells. It also suggests that the fallopian tube epithelial cells and 
normal OSE have completely different expression profiles and cannot be thought as 
reciprocal cells of origin, in fact the gene expression patterns suggest that they are 
mutually exclusive cells. Also, the reason for the OCICs clustering with the tumors and 
also with fallopian epithelial cells for the cancer related signatures can be due to the fact 
that the tumors are known to show an epithelial phenotype after they proliferate form the 
OCICs and their similarities in the expression patterns with OCICs can be indicative of 
the initiation of the development of the epithelial phenotype in the later. 
Proposed Model of Ovarian Carcinogenesis 
There has been a constant rise in the knowledge of the early events in ovarian 
cancer, which has led to a better understanding of the genesis and progression of tumors 
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in ovarian cancer. However, we propose that in a comprehensive model of ovarian 
cancer, the ovarian cancer initiating cell (OCIC) is the vital component which originated 
due to prolonged physicochemical effects on ovarian surface epithelial cells. These 
ovarian surface epithelial cells known to possess mesenchymal properties (to carry out 
postovulatory functions) conserve the mesenchymal property after their transformation to 
the malignant ovarian cancer initiating cells. The malignant properties of these cells are 
reflected by the down-regulation of various tumor suppressor pathways like TGF-beta, 
Wnt and Notch signaling pathway. During the transformation of ovarian surface 
epithelium to OCICs, many genes belonging to the tumor suppressor pathways undergo 
DNA methylation enabling the down-regulation of these pathways. These malignant 
cancer initiating cells proliferate into tumors which are differentiated cells possessing 
most of the epithelial properties and conserve the malignant properties i.e. down-
regulation of tumor suppressor pathways. The methylation subsequently is removed to 
some extent during the proliferation and differentiation of OCICs into tumor cells. The 
OCICs having inherited the mesenchymal properties will eventually migrate to distant 
sites and proliferate thus creating metastatic tumors.  
Future implications 
It is believed that standard chemotherapy procedures fail to target the tumor 
progenitor cells like ovarian cancer initiating cells. The main reason for this is that they 
express normal stem cell phenotypes like low mitotic index, enhanced DNA repair and 
expression of membrane efflux transporters (Zhang, et al., 2008). The potential DNA 
methylation markers identified in this thesis by the hypermethylation observed in the 
genes from the signature pathways like EMT, TGF-beta, Wnt and Notch can be used to 
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target and eliminate OCICs in the future therapies. The further characterization of these 
progenitors and their comprehensive studies for chromatin or Histone modifications and 
changes in miRNA expression patterns will provide us with a greater understanding in 
the alterations of these key pathways in ovarian cancer and will allow development of 
better methods for early detection of this highly elusive disease. 
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